Davis Polk, Walkers, and Cooley LLP advised on InSilico Medicine’s HK$2.62 billion Hong Kong IPO.

The IPO comprised a global offering of 94,690,500 shares priced at HK$24.05 per share, subject to an over-allotment option. The company’s shares began trading on the Hong Kong Stock Exchange on December 30, 2025, marking the largest biotechnology IPO in Hong Kong in 2025.

Morgan Stanley, CICC and GF Securities acted as joint sponsors, and as overall coordinators, joint global coordinators, joint bookrunners and joint lead managers.

Davis Polk advised InSilico Medicine on its initial public offering and listing on the Hong Kong Stock Exchange in reliance on Rule 144A and Regulation S.

The Davis Polk corporate team included Partners James C. Lin, Xuelin (Steve) Wang and Jason Xu, Counsel – registered foreign lawyer Jennifer (Yujia) Jiang, registered foreign lawyer Eva Xu and Associates Edwin Lee, Andrew Pu and Bobby Yung. Counsel Alon Gurfinkel provided tax advice. Counsel Sarah E. Kim provided advice regarding the Investment Company Act of 1940. Members of the Davis Polk team are based in the Hong Kong, Beijing, New York, and London offices.

Walkers advised InSilico Medicine Cayman TopCo on the Cayman Islands law aspects of the IPO, working closely with Davis Polk.

The Walkers team, led by Partners Andrew Barker and Mark Cummings, and supported by Senior Associates Beverly Lui and Flora Lo, and Associate Samantha Currie.

Cooley advised the underwriters in connection in connection with Insilico’s HK$2.28 billion initial public offering (IPO). Partners Michael Yu, Yiming Liu and Will Cai led the Cooley team advising the underwriters, supported by associates Hilda Li, Ying Liu, Yunxiang Xu, Brian Lau and Bridget Wang.